Alliance Pharma PLC has released a notification regarding its total voting rights in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As of 31 March 2024, the company's issued share capital consists of 540,399,740 Ordinary Shares of 1p each, resulting in the same number of voting rights. Shareholders can use this figure as the denominator for determining if they are required to notify any changes in their interest in the company under the FCA's Disclosure Guidance and Transparency Rules.
Alliance Pharma PLC, listed on AIM, is an international healthcare group focused on consumer healthcare. The company's purpose is to empower individuals to improve their health and wellbeing by making trusted and proven brands available globally. The company aims for organic growth by investing in priority brands and channels, related innovation, and selective geographic expansion. Additionally, it may consider complementary acquisitions to enhance its organic growth.
For further information, interested parties can contact Alliance Pharma PLC through the provided contact details.
This notification provides shareholders and the public with an update on the company's total voting rights and its strategic focus on empowering individuals to make a positive difference to their health and wellbeing through its consumer healthcare products.